Publications by authors named "A Blauvelt"
Purpose: Lebrikizumab is a novel, high-affinity immunoglobulin G4 monoclonal antibody that targets interleukin-13, a central mediator in atopic dermatitis (AD). In previous studies in patients with moderate-to-severe AD, lebrikizumab, administered subcutaneously via a prefilled syringe with a needle safety device (PFS-NSD), demonstrated rapid and durable dose-dependent efficacy. We assessed the pharmacokinetics and safety of lebrikizumab using either a PFS-NSD or an investigational autoinjector.
View Article and Find Full Text PDFImportance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.
Design, Setting, And Participants: PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis.
Article Synopsis
- Atopic dermatitis (AD) significantly affects patients' quality of life, causing itching, skin pain, and sleep disturbances; ruxolitinib cream has shown effectiveness in treating these symptoms in adults and adolescents through two phase III clinical trials.
- In the TRuE-AD studies, patients applied different strengths of ruxolitinib cream or a vehicle cream, with results indicating that those using ruxolitinib experienced quick relief from symptoms like skin pain and sleep issues within hours or weeks of application.
- Analysis of patient-reported outcomes revealed notable improvements in overall quality of life and symptom burden after two weeks of using ruxolitinib cream compared to the vehicle, with sustained benefits observed throughout the study periods.
Background: To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potential changes in immunogenicity.
Research Design And Methods: ADACCESS was a 51-week trial in patients with moderate-to-severe plaque psoriasis that included patients treated continuously with reference adalimumab (cH), and patients who experienced four switches between reference adalimumab and GP2017 (H2H). ADAs were measured every 6 weeks during the switching phase using an electrochemiluminescence assay.
Background: Amlitelimab, a fully human nondepleting mAb targeting OX40 ligand on antigen-presenting cells, could prevent T-cell-driven inflammation seen in atopic dermatitis (AD).
Objective: This trial evaluated the efficacy and safety of amlitelimab in adults with AD.
Methods: In this 2-part, phase 2b, randomized, double-blinded placebo-controlled trial (ClinicalTrials.